We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorStolz, Daiana
dc.contributor.authorPollak, Vincent
dc.contributor.authorChhajed, Prashant N.
dc.contributor.authorGysin, Christian
dc.contributor.authorPflimlin, Eric
dc.contributor.authorTamm, Michael
dc.date2022-08-11T08:09:32.000
dc.date.accessioned2022-08-23T16:34:39Z
dc.date.available2022-08-23T16:34:39Z
dc.date.issued2007-03-16
dc.date.submitted2009-03-16
dc.identifier.citationChest. 2007 Mar;131(3):765-72. <a href="http://dx.doi.org/10.1378/chest.06-2308">Link to article on publisher's site</a>
dc.identifier.issn0012-3692 (Print)
dc.identifier.doi10.1378/chest.06-2308
dc.identifier.pmid17356091
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38382
dc.description.abstractBACKGROUND: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing bronchoscopy. METHODS: One hundred twenty patients undergoing bronchoscopy were included. Patients with COPD were randomized to receive either 200 mug of salbutamol (n = 40) or placebo (n = 40) before bronchoscopy. Control patients (n = 40) did not receive any inhaled medication. Spirometry was performed before and 2 h after bronchoscopy in all patients. Sedative drug requirements and hemodynamic parameters were recorded. RESULTS: Hemodynamic findings before, during, and after bronchoscopy were similar in patients with COPD randomized to either salbutamol or placebo (p = not significant for all). Compared to prebronchoscopy values, postbronchoscopy percentage of predicted FEV(1) decreased significantly in all three groups: salbutamol (median, - 4.7%; interquartile range [IQR], - 13.3 to 6.6); placebo (median, - 4.8%; IQR, - 19.9 to 8.4); and control subjects (median, - 10.0%; IQR, - 20.2 to - 3.3) [p = 0.023]. The decrease in FEV(1) was similar in all three patient groups (p = 0.432). The relative change in FEV(1) was inversely correlated to the increasing severity of COPD as expressed by Global Initiative for Chronic Obstructive Lung Disease stages (p = 0.01). CONCLUSIONS: Premedication with an inhaled short-acting beta-agonist cannot be recommended in patients with COPD undergoing bronchoscopy.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=17356091&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1378/chest.06-2308
dc.subjectAdministration, Inhalation
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAlbuterol
dc.subjectBronchodilator Agents
dc.subject*Bronchoscopy
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectForced Expiratory Volume
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPremedication
dc.subjectPulmonary Disease, Chronic Obstructive
dc.subjectStatistics as Topic
dc.subjectVital Capacity
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleA randomized, placebo-controlled trial of bronchodilators for bronchoscopy in patients with COPD
dc.typeJournal Article
dc.source.journaltitleChest
dc.source.volume131
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1248
dc.identifier.contextkey782915
html.description.abstract<p>BACKGROUND: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing bronchoscopy. METHODS: One hundred twenty patients undergoing bronchoscopy were included. Patients with COPD were randomized to receive either 200 mug of salbutamol (n = 40) or placebo (n = 40) before bronchoscopy. Control patients (n = 40) did not receive any inhaled medication. Spirometry was performed before and 2 h after bronchoscopy in all patients. Sedative drug requirements and hemodynamic parameters were recorded. RESULTS: Hemodynamic findings before, during, and after bronchoscopy were similar in patients with COPD randomized to either salbutamol or placebo (p = not significant for all). Compared to prebronchoscopy values, postbronchoscopy percentage of predicted FEV(1) decreased significantly in all three groups: salbutamol (median, - 4.7%; interquartile range [IQR], - 13.3 to 6.6); placebo (median, - 4.8%; IQR, - 19.9 to 8.4); and control subjects (median, - 10.0%; IQR, - 20.2 to - 3.3) [p = 0.023]. The decrease in FEV(1) was similar in all three patient groups (p = 0.432). The relative change in FEV(1) was inversely correlated to the increasing severity of COPD as expressed by Global Initiative for Chronic Obstructive Lung Disease stages (p = 0.01). CONCLUSIONS: Premedication with an inhaled short-acting beta-agonist cannot be recommended in patients with COPD undergoing bronchoscopy.</p>
dc.identifier.submissionpathoapubs/1248
dc.contributor.departmentDepartment of Pulmonary, Allergy and Critical Care Medicine
dc.source.pages765-72


This item appears in the following Collection(s)

Show simple item record